Related Experiment Video
Updated: Feb 2, 2026

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma
Bo Xu1,2, Rui Ma2, Luke Russell2
1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Abstract:
The efficacy of oncolytic herpes simplex virus (oHSV) is limited by rapid viral clearance by innate immune effector cells and poor intratumoral viral spread. We combine two approaches to overcome these barriers: inhibition of natural killer (NK) cells and enhancement of intratumoral viral spread. We engineered an oHSV to express CDH1, encoding E-cadherin, an adherent molecule and a ligand for KLRG1, an inhibitory receptor expressed on NK cells. In vitro, infection with this engineered virus, named OV-CDH1, induced high surface E-cadherin expression on infected glioblastoma (GBM) cells, which typically lack endogenous E-cadherin. Ectopically expressed E-cadherin enhanced the spread of OV-CDH1 by facilitating cell-to-cell infection and viral entry and reduced viral clearance by selectively protecting OV-CDH1-infected cells from KLRG1+ NK cell killing. In vivo, OV-CDH1 treatment substantially prolonged the survival in GBM-bearing mouse models, primarily because of improved viral spread rather than inhibition of NK cell activity. Thus, virus-induced overexpression of E-cadherin may be a generalizable strategy for improving cancer virotherapy.
Insights
Engineered oncolytic herpes simplex virus (oHSV) expressing E-cadherin improved glioblastoma treatment by enhancing viral spread and reducing immune clearance. This strategy shows promise for improving cancer virotherapy efficacy.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Oncolytic virus therapy efficacy is limited by immune cell clearance and poor tumor spread.
- Natural killer (NK) cells contribute to viral clearance, while poor viral spread hinders intratumoral efficacy.
Purpose of the Study:
- To engineer an oncolytic herpes simplex virus (oHSV) to overcome immune clearance and enhance intratumoral spread.
- To evaluate the efficacy of the engineered oHSV expressing E-cadherin in glioblastoma models.
Main Methods:
- Engineered oHSV to express CDH1 (E-cadherin), a molecule that binds to the KLRG1 receptor on NK cells.
- Assessed E-cadherin expression, viral spread, and NK cell interactions in vitro.
- Evaluated in vivo efficacy in glioblastoma-bearing mouse models.
Main Results:
- Engineered oHSV (OV-CDH1) induced E-cadherin expression on glioblastoma cells, facilitating cell-to-cell infection and viral spread.
- Ectopic E-cadherin protected infected cells from KLRG1+ NK cell-mediated killing.
- OV-CDH1 treatment significantly improved survival in mouse models, mainly due to enhanced viral spread.
Conclusions:
- Virus-induced E-cadherin expression is a viable strategy to improve oncolytic virotherapy.
- This approach enhances viral spread and reduces immune clearance, offering a generalizable method for cancer virotherapy.
Related Concept Videos
Structure of Cadherins
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Comparing the Survival Analysis of Two or More Groups

